Nuclidium noted that studies highlighting its programs will be presented at the upcoming European Association of Nuclear Medicine (EANM) 2023 meeting.
The meeting is being held in Vienna from 9-13 September and will include presentations of positive preclinical and clinical translational data for diagnostic candidates from three of Nuclidium's precision oncology programs; namely, its copper-based theranostic CuTrace programs targeting epithelial tumors (Kalios), neuroendocrine tumors (TraceNET), and prostate cancer (NuriPro).
The data, presented in two oral presentations and a poster presentation, support the advancement of these three programs into clinical translation, the company said.
Full details on the presentations can be found here.
